Eduardo R. Pajon

5.0k total citations · 1 hit paper
22 papers, 3.4k citations indexed

About

Eduardo R. Pajon is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Eduardo R. Pajon has authored 22 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Cancer Research and 9 papers in Genetics. Recurrent topics in Eduardo R. Pajon's work include Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (9 papers) and Estrogen and related hormone effects (8 papers). Eduardo R. Pajon is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (9 papers) and Estrogen and related hormone effects (8 papers). Eduardo R. Pajon collaborates with scholars based in United States, Canada and Belgium. Eduardo R. Pajon's co-authors include Norman Wolmark, Victor G. Vogel, André Robidoux, Charles E. Geyer, Eleftherios P. Mamounas, Richard G. Margolese, Priya Rastogi, Shaker R. Dakhil, Joseph P. Costantino and James L. Hoehn and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Eduardo R. Pajon

22 papers receiving 3.3k citations

Hit Papers

Preoperative Chemotherapy: Updates of National Surgical A... 2008 2026 2014 2020 2008 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    2008 1.3k citations Priya Rastogi, Stewart Anderson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eduardo R. Pajon United States 15 1.9k 1.8k 929 729 445 22 3.4k
Rosalba Torrisi Italy 35 2.4k 1.2× 1.9k 1.1× 724 0.8× 643 0.9× 671 1.5× 130 4.2k
K Holli Finland 28 1.8k 0.9× 1.3k 0.8× 772 0.8× 468 0.6× 380 0.9× 47 3.0k
J Cuzick United Kingdom 7 2.0k 1.0× 2.0k 1.1× 1.6k 1.8× 515 0.7× 561 1.3× 10 3.6k
Marc Debled France 30 1.9k 1.0× 1.5k 0.9× 635 0.7× 662 0.9× 1.1k 2.4× 121 3.8k
Riccardo Ponzone Italy 35 1.2k 0.6× 1.2k 0.7× 599 0.6× 626 0.9× 475 1.1× 125 3.6k
Thomas Hatschek Sweden 29 2.4k 1.3× 1.9k 1.1× 754 0.8× 480 0.7× 956 2.1× 100 4.5k
Giuseppe D’Aiuto Italy 28 1.4k 0.7× 1.2k 0.7× 533 0.6× 334 0.5× 311 0.7× 90 2.8k
Larissa A. Korde United States 27 1.7k 0.9× 1.0k 0.6× 810 0.9× 681 0.9× 767 1.7× 81 3.7k
Jonathan D. Marotti United States 21 1.3k 0.7× 1.1k 0.6× 570 0.6× 376 0.5× 510 1.1× 84 2.5k
Kaija Holli Finland 26 1.7k 0.9× 1.3k 0.7× 1.3k 1.4× 537 0.7× 430 1.0× 54 3.3k

Countries citing papers authored by Eduardo R. Pajon

Since Specialization
Citations

This map shows the geographic impact of Eduardo R. Pajon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eduardo R. Pajon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eduardo R. Pajon more than expected).

Fields of papers citing papers by Eduardo R. Pajon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eduardo R. Pajon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eduardo R. Pajon. The network helps show where Eduardo R. Pajon may publish in the future.

Co-authorship network of co-authors of Eduardo R. Pajon

This figure shows the co-authorship network connecting the top 25 collaborators of Eduardo R. Pajon. A scholar is included among the top collaborators of Eduardo R. Pajon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eduardo R. Pajon. Eduardo R. Pajon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wickerham, D. Lawrence, Reena S. Cecchini, Victor G. Vogel, et al.. (2015). Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.. Journal of Clinical Oncology. 33(15_suppl). 1500–1500. 9 indexed citations
2.
Siziopikou, Kalliopi P., Stewart Anderson, Melody Cobleigh, et al.. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Research and Treatment. 142(2). 415–421. 45 indexed citations
3.
Jatoi, Aminah, Jorge J. Nieva, Rui Qin, et al.. (2012). A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. Oncology. 82(6). 315–320. 14 indexed citations
4.
Ganz, Patricia A., Stephanie R. Land, Charles E. Geyer, et al.. (2011). Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. Journal of Clinical Oncology. 29(9). 1110–1116. 91 indexed citations
5.
6.
Friday, Bret B., Chang Sik Yu, Caterina Giannini, et al.. (2011). Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-Oncology. 14(2). 215–221. 164 indexed citations
7.
Bear, Harry D., Gong Tang, Priya Rastogi, et al.. (2011). The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.. Journal of Clinical Oncology. 29(18_suppl). LBA1005–LBA1005. 33 indexed citations
8.
Siziopikou, Kalliopi P., Melody Cobleigh, Stewart Anderson, et al.. (2011). Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.. Journal of Clinical Oncology. 29(15_suppl). 588–588. 1 indexed citations
9.
Vogel, Victor G., Joseph P. Costantino, D. Lawrence Wickerham, et al.. (2010). Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prevention Research. 3(6). 696–706. 438 indexed citations
10.
Swain, Sandra M., Jong‐Hyeon Jeong, Charles E. Geyer, et al.. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. Obstetrical & Gynecological Survey. 65(11). 710–712. 10 indexed citations
11.
Laack, Nadia N., Brian Patrick O’Neill, Karla V. Ballman, et al.. (2010). CHOD/BVAM Chemotherapy and Whole-Brain Radiotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 81(2). 476–482. 12 indexed citations
12.
Swain, Sandra M., Jong‐Hyeon Jeong, Charles E. Geyer, et al.. (2010). Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. New England Journal of Medicine. 362(22). 2053–2065. 228 indexed citations
13.
Robidoux, André, Aman U. Buzdar, Emmanuel Quinaux, et al.. (2010). A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer. Clinical Breast Cancer. 10(1). 81–86. 53 indexed citations
14.
Rastogi, Priya, Stewart Anderson, Harry D. Bear, et al.. (2008). Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of Clinical Oncology. 26(5). 778–785. 1319 indexed citations breakdown →
15.
Mamounas, Eleftherios P., Jong‐Hyeon Jeong, D. Lawrence Wickerham, et al.. (2008). Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. Journal of Clinical Oncology. 26(12). 1965–1971. 239 indexed citations
16.
Land, Stephanie R., Jacek A Kopec, Reena S. Cecchini, et al.. (2007). Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. Journal of Clinical Oncology. 25(16). 2205–2211. 184 indexed citations
17.
Land, Stephanie R., D. Lawrence Wickerham, Joseph P. Costantino, et al.. (2006). Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. Obstetrical & Gynecological Survey. 61(10). 651–653. 58 indexed citations
18.
Land, Stephanie R., D. Lawrence Wickerham, Joseph P. Costantino, et al.. (2006). Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention. JAMA. 295(23). 2742–2742. 174 indexed citations
19.
Ganz, PA, Stephanie R. Land, D. L. Wickerham, et al.. (2006). The study of tamoxifen and raloxifene (STAR): First report of patient-reported outcomes (PROs) from the NSABP P-2 Breast Cancer Prevention Study. Journal of Clinical Oncology. 24(18_suppl). LBA561–LBA561. 4 indexed citations
20.
Pandya, Kishan J., Gary R. Morrow, Joseph A. Roscoe, et al.. (2005). Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. The Lancet. 366(9488). 818–824. 231 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosalba Torrisi Breakdown of academic impact, for papers by K Holli Breakdown of academic impact, for papers by J Cuzick Breakdown of academic impact, for papers by Marc Debled Breakdown of academic impact, for papers by Riccardo Ponzone Breakdown of academic impact, for papers by Thomas Hatschek Breakdown of academic impact, for papers by Giuseppe D’Aiuto Breakdown of academic impact, for papers by Larissa A. Korde Breakdown of academic impact, for papers by Jonathan D. Marotti Breakdown of academic impact, for papers by Kaija Holli
Rankless by CCL
2026